MAP3K5 and metabolic dysfunction-associated steatohepatitis: At the moment, the Phase II clinical trial for selonsertib, inhibitor of the apoptosis signal-regulating kinase-1 (ASK-1) in the MAP-kinases cascade, did not reveal dangerous side effects and induced an amelioration of NASH and fibrosis as well as of serum biomarkers of apoptosis and necrosis in patients [168].